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Edited by Gerrit van MeerAbstract Ostreolysin, a 15 kDa pore-forming protein from the
edible oyster mushroom (Pleurotus ostreatus), is lytic to
membranes containing both cholesterol and sphingomyelin. Its
cytotoxicity to Chinese hamster ovary cells correlates with their
cholesterol contents and with the occurrence of ostreolysin in the
cells detergent resistant membranes. Moreover, ostreolysin binds
to supported monolayers and eﬃciently permeabilizes sonicated
lipid vesicles, only if cholesterol is combined with either
sphingomyelin or dipalmitoylphosphatidylcholine. Addition of
mono- or di-unsaturated phosphatidylcholine to the cholesterol/
sphingomyelin vesicles dramatically reduces the ostreolysin’s
activity. It appears that the protein recognizes speciﬁcally a
cholesterol-rich lipid phase, probably the liquid-ordered phase.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ostreolysin (Oly) [1,2] is a representative of the aegerolysin
protein family (Pfam Accession No. PF06355). So far, these
proteins have been found in the bacteria Clostridium bifer-
mentans [3] and Pseudomonas aeruginosa (TrEMBL Accession
No. Q9I710), moulds Aspergillus fumigatus [4] and Neurospora
crassa (TrEMBL Accession No. Q8WZT0), and mushrooms
Pleurotus ostreatus and Agrocybe aegerita [1,5]. It has been
suggested that they may have a role in processes such as* Corresponding author. Fax: +386-1-2573390.
E-mail address: peter.macek@bf.uni-lj.si (P. Macek).
Abbreviations: CHO, Chinese hamster ovary; Chol, cholesterol;
DOPC, dioleoylphosphatidylcholine; DPPC, dipalmitoylphos-
phatidylcholine; DRMs, detergent resistant membranes; EDTA, eth-
ylene-diaminotetraacetic acid; Erg, ergosterol; FCS, fetal calf serum;
HEPES, 1-piperazineethane sulfonic acid, 4-(2-hydroxyethyl)-
monosodium salt; Ld, liquid-disordered; Lo, liquid-ordered; LPPS,
lipo-protein poor serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide; Oly, ostreolysin; PBS, phosphate-buﬀered
saline; POPC, palmitoyloleoylphosphatidylcholine; SM, sphingomye-
lin; SPR, surface plasmon resonance; SV, sonicated vesicles
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doi:10.1016/j.febslet.2004.07.093modulation of bacterial sporulation [3], virulence of
A. fumigatus [4], and mushroom fruiting [6].
Oly interacts with lipids and forms pores in eukaryotic cell
membranes and lipid vesicles prepared from total membrane
lipids [2]. So far, searching for a speciﬁc lipid acceptor of the
proteins belonging to the aegerolysin protein family has not
been successful. Lysophospholipids have been reported to be
inhibitors of Asp-hemolysin from A. fumigatus [7] and Oly,
but no direct interaction with lysophospholipids could be
proved for Oly [2]. Very recently, an Oly isoform from P. os-
treatus, pleurotolysin A, was suggested to be an SM-inhibited
hemolysin [5].
Here, we addressed the question of membrane lipid accep-
tor(s) for ostreolysin. We provide evidence that ostreolysin is
partitioned in both cell and artiﬁcial lipid membrane detergent
resistant membranes (DRMs). Moreover, its binding to lipid
mono- and bilayers, and lipid vesicle permeabilization, is
speciﬁcally dependent on the presence of both cholesterol
(Chol) and sphingomyelin (SM). SM can be replaced by sat-
urated dipalmitoylphosphatidylcholine (DPPC); however, this
results in the decreased activity of Oly.2. Materials and methods
2.1. Ostreolysin and lipids
Ostreolysin was isolated from immature mushroom fruit bodies and
N-sequenced to check purity as described [1]. In addition, its homo-
geneity was conﬁrmed by ESI-mass spectroscopy, which gave an Mr
for ostreolysin of 14975.4. Dioleoylphosphatidylcholine (DOPC),
DPPC, palmitoyloleoylphosphatidylcholine (POPC), egg phosphati-
dylethanolamine, wool grease Chol, and porcine brain SM were ob-
tained from Avanti Polar Lipids (USA). Ergosterol was from Fluka
(Switzerland) and ganglioside GM1 from Serva (Germany).
2.2. Cytotoxicity assay
To determine the inﬂuence of cell membrane Chol on the Oly cy-
totoxicity, we used Chinese hamster ovary wild-type CHO-K1 and
CHO-215 cells with deﬁcient Chol synthesis (impaired 4-carboxysterol
decarboxylase) [8], grown in a McCoy’s 5A medium (Sigma, Germany)
with 10% fetal calf serum (FCS) at 37 C and 5% CO2. Cells were
plated overnight in 96-well microtiter plates (Costar, USA) at a con-
centration of 5 · 103 cells/well in the growth medium. After washing
them with a Dulbecco’s PBS buﬀer, fresh growth medium, with either
10% FCS or a lipoprotein poor serum (LPPS) with diminished Chol
contents [8,9], was added. After 24 h, the cells were treated with 1 lg/
ml Oly for 0–25 min. Cells were then washed three times with theblished by Elsevier B.V. All rights reserved.
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assay [2]. The treated cells were inspected under a phase-contrast
microscope.
2.3. Isolation of DRMs and Oly Western immunoblotting
DRMs were isolated from the cells or sonicated vesicles (SV) by
Triton X-100 (0.5% v/v) extraction as described in detail before [9,10].
In the growth media, 2–5 107 cells were pre-treated with 2.5 lg/ml
Oly for 15 min at 23 C before the detergent extraction. The pelleted
cells, lysed for 30 min at 0 C by 0.5% Triton X-100 in buﬀered saline
(25 mM 1-piperazineethane sulfonic acid, 4-(2-hydroxyethyl)-mono-
sodium salt (HEPES), 150 mM NaCl, 1 mM ethylene-diaminotetra-
acetic acid (EDTA), 1 mM phenylmethylsulfonyl ﬂuoride, and 10 lg/
ml aprotonin, pH 6.5), were mixed (1/1, v/v) with 85% sucrose (w/v) in
the same buﬀer mixture. In a centrifuge tube, the resulting 42.5% su-
crose mixture was overlaid successively with 5 ml of a 35 and 5% (w/v)
sucrose gradient in the buﬀered saline supplemented with 1 mM EDTA
and 1 mM Na3VO4. Following 18 h centrifugation at 4 C (200 000·g,
SW41 rotor, Beckman L8-M preparative centrifuge), centrifuged su-
crose fractions were collected and analyzed for Oly using Western
immunoblotting. Proteins were stained with rabbit anti-Oly polyclonal
and secondary goat anti-rabbit horseradish peroxidase-conjugated
antibodies [1]. Chol contents/mg of cell DRMs protein were deter-
mined as reported [8,9]. Using the same procedure as for the cell
DRMs, SV DRMs were isolated after treatment of 10 mg/ml SV with
100 lg/ml Oly in 140 mM NaCl, 20 mM Tris–HCl, and 1 mM EDTA,
pH 8.0, for 15 min at room temperature. In that case, only fractions
containing visible Triton X-100-insoluble lipids were analyzed for Oly
as described above.
2.4. Lipid vesicles and measurement of calcein release
Sonicated vesicles, either without or loaded with 80 mM calcein
(Sigma), were prepared by sonication of 4–20 mg/ml lipids in 140 mM
NaCl, 20 mM Tris–HCl, and 1 mM EDTA, pH 8.0. Non-encapsulated
80 mM calcein was removed on a Sephadex G-50 column. After son-
ication and centrifugation, the lipid concentration of SV suspensions
(without calcein) was determined colorimetrically with Waco Free
Cholesterol C and Wako test Phospholipids B (990-54009) kits (Waco
Chemicals GmbH, Germany) in order to quantify total lipids in sus-
pension and to check the cholesterol/phospholipid ratio. Before use,
the sonicated vesicles were kept overnight at room temperature to
avoid their instability due to fusion [11]. Size of SV was estimated by
photon correlation spectroscopy on a Zeta Sizer instrument (Malvern
Instruments, UK) as reported before [2].
Permeabilization of SV was measured as the increase in ﬂuorescence
intensity of calcein (exc./em. wave length, 485/535 nm), dequenched on
release from SV, in a ﬂuorescence microplate reader Tecan 02A (Te-
can, Austria). The time-course of increasing ﬂuorescence intensity, Ft,
was ﬁtted to a stretched exponential equation used in various chemical
and physical rate processes in disordered media [12]:
Ft ¼ Fmin þ Fmax  ð1 expðk  tÞbÞ ð1Þ
where Fmin and Fmax are the starting and ﬁnal ﬂuorescence intensities, k
is a rate constant, and b an exponential scaling factor. Cooperativity of
the permeabilization process was estimated by determining the slope of
the log–log dependence of the relative rate of permeabilization on
concentration of Chol or Oly.
2.5. Hemolysis assay and inhibition of ostreolysin by lipids
Binding of Oly to SV (without encapsulated calcein) was estimated
by measuring the hemolytic activity of the free Oly fraction after pre-
incubation of 0.2 lg/ml Oly with varied concentration of SV lipids for
30 min at 37 C. The lipid concentration necessary for reducing the
rate of hemolysis of bovine erythrocytes by 50%, IC50, was determined
in a MRX microplate reader (Dynex Technologies, Germany) as de-
scribed [2].
2.6. EPR spectroscopy
EPR spectroscopy was used to evaluate potential eﬀect of ostreolysin
on the domain structure of lipid vesicles and their ﬂuidity character-
istics [13]. SV (20 mg/ml lipids, without calcein) were spin-labeled with
MeFASL (10.3) (N-oxyl-2-undecyl-2-(30-methoxycarbonyl)-propyl-
4,4-dimethyloxazolidine, provided by Prof. S. Pecar, University of
Ljubljana) using a molar ratio of 200:1. Spectra were taken on a X-
band EPR spectrometer ESP 300 (Bruker, Germany) at temperaturesranging between 20 and 40 C as described [14]. EPR spectra were
analyzed with an EPRSIM Ver 4.9 software package for simulation of
the spectra of nitroxide spin labels [13]. The simulation method takes
into account the fact that the spectra are composed of several com-
ponents that belong to the spin labels in diﬀerent types of coexisting
membrane regions with diﬀerent ordering and dynamics of the alkyl
chains. From the best ﬁt to the experimental spectra, a number of the
coexisting domains, their order parameter, rotational correlation time,
and the corresponding portion of each region in the membrane of SV
were derived. The eﬀect of Oly on the parameters p and S was studied
at a lipid/protein molar ratio of 100:1.
2.7. SPR determination of binding of ostreolysin to lipid monolayers
Oly binding to lipid monolayers was determined in a Biacore X
surface plasmon resonance (SPR) apparatus (Biacore AB, Sweden).
Monolayers were deposited on a HPA Chip (Biacore AB) using SV
(0.5 mM lipids in 140 mM NaCl, 20 mM Tris–HCl, and 1 mM
EDTA, pH 8.0) as recommended by the producer. Dissolved in the
same buﬀer, Oly (0.081, 0.162, 0.325, 0.75, and 1.2 mg/ml) was injected
at a ﬂow rate of 40 ll/min and sensorgrams were recorded at 25 C.
Bulk controls were run without protein.3. Results and discussion
In membranes, dynamic complexion of cholesterol with
sphingomyelin and saturated glycerophosphatides results in
liquid-ordered, Lo, and disordered, Ld, lipid phases [15]. This is
the basis for the formation of separate lipid domains, lipid
rafts (operationally DRMs). In cell membranes, rafts are en-
riched in cholesterol, sphingolipids, and speciﬁc proteins. They
have roles in membrane traﬃcking and signaling [16–18], and
are attachment/entry sites for cell pathogens, toxins and other
ligands [19,20].
Our preliminary screening for lipid acceptor(s) had demon-
strated that only vesicles reconstituted from erythrocyte
neutral lipids (mainly Chol) and phospholipids (SM and
glycerophosphatides) could be permeabilized by Oly. This
observation has suggested a speciﬁc cholesterol-induced lipid
microdomain, such as Lo phase, which is characteristic of lipid
rafts, to be a possible binding site. To check this hypothesis, we
ﬁrst employed wild-type CHO-K1 and mutant CHO-215 cells,
with impaired Chol synthesis, to assess dependence of Oly
cytotoxicity on the cell membrane contents of Chol and oc-
currence of Oly in DRMs. Fig. 1 demonstrates that (i) Oly is
more cytotoxic to cells, both wild-type and mutant, grown in
the presence of serum Chol and (ii) the higher the cellular Chol
level, the more abundant is Oly in the cells’ DRMs. Despite the
lower content of Chol, the mutant cells appear more sensitive
to Oly, which could be the consequence of the lower viability
of the cells with deﬁcient Chol-synthesis as observed before
[9,10]. Microscopy revealed that the extent of cytotoxicity
correlated well with changes of cell shape, cell membrane
blebbing, and cell lysis (not shown), similar to that observed
for some tumor cells exposed to Oly [2].
So far, screening of dispersions of pure Chol, SM, DPPC,
and some other phospholipids, or binary mixtures of phos-
pholipids for inhibition of hemolysis produced by Oly has
failed to reveal speciﬁc acceptor lipid(s) [1,2]. Following this
fact and the results in Fig. 1, we used artiﬁcial lipid membranes
to study Oly preference for lipid mixtures typical of DRMs.
Only SV composed of Chol combined with either SM or DPPC
exerted inhibition of hemolysis, as indicated by IC50 values in
Table 1. None of the other combinations tested (up to 20
mg/ml lipids), such as those including POPC, DOPC or egg
phosphatidylethanolamine, was inhibitory. The striking ﬁnd-
Fig. 2. Permeabilization of sonicated lipid vesicles by ostreolysin.
(A) Representative time course of changes of dequenched ﬂuorescence
intensity of calcein released from Chol/SM 2:3 SV upon Oly treatment
at the indicated lg/ml concentrations. 1 mM Triton X-100 (Tx-100)
was used for 100% release of encapsulated ﬂuorophore as designated
for 17 lg/ml Oly by the arrow. Permeabilization of 20 lg/ml SV with
indicated molar ratio of lipids was characterized by rate constant k
(B) and percentage of calcein release (C) derived by ﬁtting a time
course to a stretched exponential function (see Section 2).
Fig. 1. Cytotoxicity of Oly and its occurrence in DRMs. Wild-type
CHO-K1 (A) and CHO-215 cells with deﬁcient Chol synthesis (B)
grown in the presence of 10% FCS (normal cholesterol level) (closed
squares, Chol+) or a lipoprotein poor serum with decreased Chol
(open squares, Chol)) were treated with 1 lg/ml Oly for the indicated
time, and viability was assayed with an MTT test. Viability (%) was
expressed as the ratio between formazan absorbance at 570 nm of
treated cells at diﬀerent time intervals and control cells at the beginning
of the experiment (0 min). Means and S.E. values of 5–8 replicates are
shown. DRMs were isolated as described in Section 2 and fractions 1–8
immunoblotted for Oly detection (insets). For CHO-K1 cells grown in
the presence of FCS or LPPS, the concentration of Chol in DRMs was
approx. 22 or 15 lg/mg protein, while for CHO-215 12 or 6 lg/mg.
Visible cholesterol-rich fractions were 3–5.
Table 1
Lipid composition of sonicated vesicles, dimensions, and inhibition of
ostreolysin-induced hemolysis
Composition (molar ratio) Diameter (nm) IC50 (mg/ml)
Chol:SM 1:9 104 1 17
Chol:SM 2:8 123 2 15
Chol:SM 3:7 88 1 11
Chol:SM 4:6 94 1 6.6
Chol:SM 5:5 91 1 1.0
Chol:SM 6:4 97 3 0.1
Chol:DOPC 1:1 119 2 20
Chol:POPC 1:1 71 6 20
Chol:DPPC 1:1 98 3 3
Mean diameter DS.D. (standard deviation) was estimated by pho-
ton correlation spectroscopy. IC50 is the concentration of lipids that
decreases the rate of hemolysis of bovine erythrocytes by 50% [2].
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is only in combination with either SM or the saturated phos-
phatidylcholine species, strongly suggested that the protein
might recognize a speciﬁc Chol-induced lipid phase.
As shown in Fig. 2, we studied in more detail the dependence
of SV permeabilization on speciﬁc Chol binary or ternary lipid
mixtures allowing formation of the Lo phase and lipid rafts[21–23]. Time courses of calcein release, quantifying permea-
bilization activity as exempliﬁed in Fig. 2A, were used to derive
a rate constant k and the percentage of maximal calcein release
at diﬀerent ﬁnal Oly concentrations (Fig. 2B and C). The
highest rate and extent of calcein release is pertinent to the
Chol/SM SV, while those obtained with Chol/DPPC are ap-
prox. 20 times lower. POPC, 20 mol%, in SV containing Chol/
SM (1:1) reduces both k and the percentage of release by ap-
prox. 60-fold, while at 33%, it results in a decrease of k by
1000-fold. Inclusion of 1% ganglioside GM1, well-known to
be preferentially associated into the Lo lipid phase [24], has no
eﬀect on Oly permeabilizing activity. Replacement of Chol by
the fungal sterol ergosterol in SV has a similar eﬀect, but at a
very much lower eﬃciency (Fig. 2B, C). In this respect, it is
known that sterols other than Chol, typical for fungi or plants,
and Chol precursors, have a similar function in lipid raft
maintenance [25,26].
Detergent extraction of cell and artiﬁcial lipid membranes
may produce artifact DRMs [27,28] and, therefore, inclusion
of Oly in the cell and lipid DRMs might be an artifact.
However, this seems unlikely due to the SPR results in Fig. 3,
Fig. 3. Binding of ostreolysin to lipid mono- and bilayers. (A) 1,2 mg/
ml Oly in 140 mM NaCl, 20 mM Tris–HCl, and 1 mM EDTA, pH 8.0,
was injected at a ﬂow rate of 40 ll/min over indicated Chol/lipid 1/1
monolayers. The sensorgrams were corrected for bulk eﬀects; RU,
response units. Decrease of the signal at the end of injection is either an
artifact due to a rather low injected volume or results from Oly’s in-
duced lipid desorption. (B) Binding of Oly to Chol/lipid 1/1 SV. In 140
mM NaCl and 20 mM Tris–HCl, pH 8.0, 0.5 ml of SV (10 mg/ml) was
pre-incubated with 50 ll of Oly (1 mg/ml) for 15 min at room tem-
perature and visible DRMs were isolated and immunoblotted to detect
DRM-bound Oly, as compared to Oly control without lipids and ka-
leidoscopic molecular weight markers.
Fig. 4. Eﬀect of cholesterol to sphingomyelin ratio on permeabilization
of SV by Oly. Calcein-loaded Chol/SM SV containing indicated mole%
ofCholwere treatedwith 0.25–130lg/mlOly to obtain the time course of
calcein release, then rate constant k (A) and percentage of release (B)
were derived (see Fig. 2 and Section 2). (C) Relative rate of release,
normalized to 100% release (see (B)), was calculated as vrel ¼ k (maxi-
mal percentage of release) and used to estimate slope of the curve n from
a standard double-log plot. Coeﬃcient n (2–45) implies degree of co-
operativity of the permeabilization process with respect to Chol. In (C),
numbers show the respective lg/ml concentration of Oly.
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shown. Further, incubation of spin labeled Chol/SM (1: 1) SV
with Oly had no eﬀect on their EPR spectra (not shown). This
evidence thus supports the conclusion that the permeabilizing
eﬀect of Oly results from its direct recognition of an existing
speciﬁc lipid complex, rather than any eﬀect on recruiting and
ordering of lipids.
Formation of a transmembrane pore by pore-forming pro-
teins is a multi-step process that includes binding to the
membrane and in-plane protein oligomerization [29,30]. Cer-
tain of such proteins may exploit cholesterol or SM for binding
or protein insertion. Chol is crucial for permeabilization of
bacterial cholesterol-dependent cytolysins but not for binding
and pre-pore formation on the membrane [30]. An exception is
perfringolysin O and its C-terminal domain, of which binding
step is cholesterol-speciﬁc [31]. Another cytolysin, lysenin, uses
SM as a binding acceptor [32], as also suggested for pleuro-
tolysin A [5]. To discriminate between the possible eﬀects of
the speciﬁc Chol/lipid composition on either binding or pore-
formation by Oly, we used SPR to detect directly its binding to
lipid monolayers [29,33]. In Fig. 3, only sensorgrams obtained
at the highest Oly concentration of 1.2 mg/ml are shown be-
cause no Oly binding to Chol/POPC could be observed below
this concentration. On the Chol/SM monolayer, saturation
with ostreolysin was observed by increasing the protein con-centration (not shown); a half-saturation concentration was
90 lg/ml. The eﬃciency of Oly binding, in the order Chol/
SMChol/DPPC > Chol/POPC and no binding to the Chol/
DOPC monolayers (Fig. 3A), strongly suggests that the
binding step is essentially dependent on the speciﬁc Chol/lipid
composition. This is also supported by partition of Oly into SV
DRMs (Fig. 3B). There is evidence that the coexistence of Lo,
Ld, and some other lipid domains, together with their contents,
is dependent on the Chol/lipid(s) ratio [23,34,35]. We, there-
fore, analyzed in more detail the eﬀect of the Chol/SM ratio on
the permeabilizing activity of Oly in SV (Fig. 4). The rate
constants and extent of calcein release coincide with increased
Chol. The concentrations of Chol (above 30 mol%) that pro-
duce detectable permeabilization are similar to those inducing
the Lo lipid phase in mono- and bilayers [23,34]. If the marked
K. Sepcic et al. / FEBS Letters 575 (2004) 81–85 85activity is dependent on a Chol-rich phase, then one should
expect that Oly interacts with certain Chol complexes. We used
the method of initial rate estimates of the permeabilization
curves to derive the coeﬃcient n with respect to Chol con-
centration (Fig. 4C). The slope reveals unusual ever-increasing
values for n, from 2 to about 45. In contrast, n determined
for Oly from the plot of log vrel vs. log conc. of Oly was uni-
formly equal to  2.3 over its whole concentration range (not
shown), in agreement with the previously reported Oly oligo-
merization on vesicles made of erythrocyte lipids [2]. The in-
creasing Chol cooperativity suggests that Oly interacts with
speciﬁc Chol-containing complexes, which may grow with in-
creasing Chol concentration. On the other hand, the opposing
eﬀect of POPC (see Fig. 2) implies that mono- and di-unsat-
urated lipids promote dissociation of productive Chol-rich
complexes and thus prevent interaction with Oly.4. Conclusions and perspectives
So far, the majority of studies of lipid domains were per-
formed on monolayers or giant unilamellar vesicles. Our study
suggests, however, that the speciﬁc cholesterol-rich phases
could be studied just as well in vesicles of a smaller diameter
(see Table 1). It is evident that Oly does not interact with either
pure Chol or SM but that it does react, speciﬁcally, with a
Chol-rich lipid phase, the integrity of which is highly sensitive
to unsaturated glycerophosphatides. The underlying mecha-
nism could be dissociation of Chol-complexes by unsaturated
phospholipids and, in turn, increase of chemical activity of
Chol [24]. According to recent data, we suggest that the Chol-
induced phase may be the Lo phase, however, some other
unprecedented Chol-rich lipid phase, dependent on the pres-
ence of saturated phosphatidylcholines in the membrane,
cannot be excluded. In fact, the diversity of Chol-rich lipid
phases in membranes in terms of the stoichiometry of Chol/
Chol and/or Chol/other lipid complexes is not obvious [15,24].
The properties of Oly described here thus make Oly and its
engineered mutants – for example, fused with ﬂuorescent
proteins or labeled with ﬂuorescent, as reported for perfring-
olysin O [36], or spin probes – a new tool in further studies of
Chol-rich lipid phases and Chol-complexes in natural and
artiﬁcial lipid membranes.
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